Trial Profile
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Tazarotene (Primary)
- Indications Acne vulgaris
- Focus Registrational; Therapeutic Use
- Sponsors Stiefel Laboratories
- 07 Apr 2014 New trial record
- 14 Nov 2011
- 02 Nov 2010